Table 2.

GRADEpro evidence grading.

Certainty assessment							No of patients		Effect		Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	CHM	control	Relative (95% CI)	Absolute (95% CI)
6MWD
6	randomized trials	seriousa	seriousb	not serious	not serious	publication bias strongly suspectedc	444	440	–	MD 59.66 higher (55 higher to 64.32 higher)	⊕◯◯◯ VERY LOW	CRITICAL
6MWD-NON-BLINDED TRIALS
5	randomized trials	seriousa	not serious	not serious	not serious	publication bias strongly suspectedc	384	380	–	MD 52.13 higher (46.91 higher to 57.34 higher)	⊕⊕◯◯ LOW	CRITICAL
6MWD-SINGLE-BLINDED TRIAL
1	randomized trials	not serious	not serious	not serious	not serious	none	60	60	–	MD 89.1 higher (78.79 higher to 99.41 higher)	⊕⊕⊕⊕ HIGH	CRITICAL
MLHFQ
4	randomized trials	seriousa	seriousb	not serious	not serious	none	285	285	–	MD 6.7 lower (8.35 lower to 5.06 lower)	⊕⊕◯◯ LOW	CRITICAL
MLHFQ-60 CASES OF EACH GROUP
3	randomized trials	seriousa	not serious	not serious	not serious	none	180	180	–	MD 4.95 lower (7.19 lower to 2.7 lower)	⊕⊕⊕◯ MODERATE	CRITICAL
MLHFQ-105 CASES OF EACH GROUP
1	randomized trials	seriousa	not serious	not serious	not serious	none	105	105	–	MD 8.73 lower (11.15 lower to 6.31 lower)	⊕⊕⊕◯ MODERATE	CRITICAL
SF-36
2	randomized trials	seriousa	not serious	not serious	not serious	none	125	125	–	SMD 0.66 higher (0.34 higher to 0.99 higher)	⊕⊕⊕◯ MODERATE	CRITICAL

CI, confidence interval; MD, mean difference; SMD, standardized mean difference.

^ano-blinded.

^bI² > 50%.

^cselective reporting.